Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Calquence combined with venetoclax showed a 35% decrease in disease progression or mortality risk compared to chemoimmunotherapy. Calquence’s safety and tolerability were found to be consistent with ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

Calquence is approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US, Japan and China, and approved for CLL in the EU and many other countries.

AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...